Myriad wins diagnostics IP case

Myriad Genetics ($MYGN) scored a win with a federal court's ruling that the company's claims on genes that predict risk of breast and ovarian cancers can be patented, bringing a close to the company's lengthy battle to secure its intellectual property and encouraging biotechs with heavy interests in genetic research. Report

Like what you're reading?
Click here to get more news like this delivered to your inbox every day >>